iSign Solutions (ISGN) 10-Q 14 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 14, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Communication Intelligence Corp	'
Entity Central Index Key	'0000727634	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'Yes	'
EntityVoluntaryFilers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	225,824,328

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$287	$486
Accounts receivable, net of allowance of $0 at September 30, 2013 and $27 at December 31, 2012	259	701
Prepaid expenses and other current assets	78	73
Total current assets	624	1,260
Property and equipment, net	20	28
Patents, net	1,380	1,655
Other assets	29	29
Total assets	2,053	2,972
Current liabilities:	'	'
Short-term notes payable	750	'
Accounts payable	256	75
Accrued compensation	256	289
Other accrued liabilities	190	150
Deferred revenue	589	569
Total current liabilities	2,041	1,083
Deferred revenue long-term	'	249
Deferred rent	99	125
Derivative liability	37	128
Total liabilities	2,177	1,585
Commitments and Contingencies	'	'
Stockholders' (deficit) equity	'	'
Common Stock, $0.01 par value; 1,500,000 shares authorized; 232,324 issued, 225,824 outstanding at September 30, 2013 and 231,023 shares issued and 224,523 outstanding at December 31, 2012	2,322	2,309
Treasury shares, 6,500 shares at September 30, 2013 and December 31, 2012, respectively	-325	-325
Additional paid in capital	94,664	95,262
Accumulated deficit	-117,684	-114,420
Accumulated other comprehensive loss	-15	-29
Total CIC stockholders' equity	412	1,923
Non-Controlling interest	-536	-536
Total Stockholders' (deficit) equity	-124	1,387
Total liabilities and shareholders' (deficit) equity	2,053	2,972
Series A-1 Preferred Stock [Member]	'	'
Stockholders' (deficit) equity	'	'
Preferred stock by class of stock	1,011	953
Series B Preferred Stock [Member]	'	'
Stockholders' (deficit) equity	'	'
Preferred stock by class of stock	8,959	8,188
Series C Preferred Stock [Member]	'	'
Stockholders' (deficit) equity	'	'
Preferred stock by class of stock	4,920	4,754
Series D-1 Preferred Stock [Member]	'	'
Stockholders' (deficit) equity	'	'
Preferred stock by class of stock	2,278	2,158
Series D-2 Preferred Stock [Member]	'	'
Stockholders' (deficit) equity	'	'
Preferred stock by class of stock	$4,282	$3,073

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Current assets:	'	'
Accounts receivable, allowance	$0	$27
Stockholders' (deficit) equity	'	'
Common Stock, par value	$0.01	$0.01
Common Stock, shares authorized	1,500,000,000	1,500,000,000
Common Stock, shares issued	232,324,000	231,023,000
Common Stock, shares outstanding	225,824,000	224,523,000
Treasury shares	6,500,000	6,500,000
Series A-1 Preferred Stock [Member]	'	'
Stockholders' (deficit) equity	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	1,011,000	953,000
Preferred stock, shares outstanding	1,011,000	953,000
Preferred stock, liquidation preference	1,011	'
Series B Preferred Stock [Member]	'	'
Stockholders' (deficit) equity	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	14,000,000	14,000,000
Preferred stock, shares issued	10,830,000	10,058,000
Preferred stock, shares outstanding	10,830,000	10,058,000
Preferred stock, liquidation preference	16,245	'
Series C Preferred Stock [Member]	'	'
Stockholders' (deficit) equity	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	9,000,000	9,000,000
Preferred stock, shares issued	4,496,000	4,175,000
Preferred stock, shares outstanding	4,496,000	4,175,000
Preferred stock, liquidation preference	6,743	'
Series D-1 Preferred Stock [Member]	'	'
Stockholders' (deficit) equity	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	1,449,000	1,124,000
Preferred stock, shares outstanding	1,449,000	1,124,000
Preferred stock, liquidation preference	1,449	'
Series D-2 Preferred Stock [Member]	'	'
Stockholders' (deficit) equity	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	8,000,000	8,000,000
Preferred stock, shares issued	4,511,000	3,302,000
Preferred stock, shares outstanding	4,511,000	3,302,000
Preferred stock, liquidation preference	$4,511	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue:	'	'	'	'
Product	$195	$355	$358	$1,231
Maintenance	175	161	509	477
Total revenues	370	516	867	1,708
Cost of sales:	'	'	'	'
Product	54	87	63	308
Maintenance	45	9	194	48
Research and development	471	441	1,563	1,247
Sales and marketing expense	291	329	884	1,059
General and administrative expense	414	426	1,506	1,388
Total operating costs and expenses	1,275	1,292	4,210	4,050
Loss from operations	-905	-776	-3,343	-2,342
Other expense, net	-2	-3	-3	-9
Interest expense:	'	'	'	'
Related party	-6	-30	-9	-88
Other	'	-34	'	-57
Amortization of loan discount and deferred financing:	'	'	'	'
Related party	'	-5	'	-13
Other	'	-7	'	-16
Gain on derivative liability	26	43	91	149
Net loss	-887	-812	-3,264	-2,376
Accretion of beneficial conversion feature, preferred shares:	'	'	'	'
Related party	-23	-93	-164	-767
Other	-14	-58	-195	-201
Preferred stock dividends:	'	'	'	'
Related party	-281	-158	-717	-370
Other	-225	-51	-614	-121
Income tax	'	'	'	'
Net loss before non-controlling interest	-1,430	-1,172	-4,954	-3,835
Net loss attributable to non-controlling interest	'	'	'	'
Net loss attributable to common stockholders	($1,430)	($1,172)	($4,954)	($3,835)
Basic and diluted loss per common share	($0.01)	($0.01)	($0.02)	($0.02)
Weighted average common shares outstanding, basic and diluted	225,824	224,492	225,810	222,198

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Comprehensive income:	'	'	'	'
Net loss	($887)	($812)	($3,264)	($2,376)
Foreign currency translation adjustment	'	1	'	5
Total comprehensive loss	($887)	($811)	($3,264)	($2,371)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net loss	($3,264)	($2,376)
Adjustments to reconcile net loss to net cash used for operating activities:	'	'
Depreciation and amortization	287	365
Amortization of debt discount and deferred financing costs	'	29
Stock-based employee compensation	560	376
Restricted stock expense	'	2
Series C Preferred issued in settlement of indemnity claim	'	417
Common Stock received as settlement of 16b claim	'	-325
Warrants issued for services	'	3
(Loss) gain on derivative liability	-91	-149
Changes in operating assets and liabilities:	'	'
Accounts receivable, net	442	-216
Prepaid expenses and other assets	-5	-165
Accounts payable	181	75
Accrued Compensation	-33	76
Other accrued liabilities	28	-37
Deferred revenue	-229	-136
Net cash used in operating activities	-2,124	-2,061
Cash flows from investing activities:	'	'
Acquisition of property and equipment	-4	-8
Net cash used in investing activities	-4	-8
Cash flows from financing activities:	'	'
Proceeds from issuance of short-term notes payable	1,000	2,328
Proceeds from exercise of warrants for cash	29	213
Proceeds from exercise of stock options	'	12
Payments on short term notes payble	-250	-225
Net cash provided by financing activities	1,929	2,328
Effect of exchange rate changes on cash and cash equivalents	'	'
Net (decrease) increase in cash and cash equivalents	-199	259
Cash and cash equivalents at beginning of period	486	307
Cash and cash equivalents at end of period	287	501
Supplemental disclosure of cash flow information:	'	'
Interest paid	2	'
Income tax paid	'	'
Non-cash financing and investing transactions:	'	'
Dividends on preferred shares	1,331	491
Accretion of beneficial conversion feature for dividends on preferred shares	201	968
Cashless exercise of warrants	'	202
Series B Preferred Stock [Member]	'	'
Non-cash financing and investing transactions:	'	'
Conversion of Preferred Stock into Common Stock	'	140
Series C Preferred Stock [Member]	'	'
Non-cash financing and investing transactions:	'	'
Conversion of Preferred Stock into Common Stock	'	39
Series D-1 Preferred Shares	'	'
Cash flows from financing activities:	'	'
Proceeds from issuance of Preferred shares	230	'
Non-cash financing and investing transactions:	'	'
Accretion of beneficial conversion feature on issuance of preferred shares	158	'
Series D-2 Preferred Shares	'	'
Cash flows from financing activities:	'	'
Proceeds from issuance of Preferred shares	$920	'

Nature_of_business_basis_of_pr

Nature of business, basis of presentation and summary of significant accounting policies	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of business, basis of presentation and summary of significant accounting policies	'
	1. Nature of business and summary of significant accounting policies
	Basis of Presentation
	The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2012.
	The accompanying unaudited condensed consolidated financial statements of Communication Intelligence Corporation and its subsidiary (the "Company" or "CIC") have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year.
	The Company is a leading supplier of electronic signature products and the recognized leader in biometric signature verification. CIC enables companies to achieve truly paperless workflow in their electronic business processes by providing multiple signature technologies across virtually all applications. CIC's solutions are available both in software-as-a-service ("SaaS") and on-premise delivery models and afford "straight-through-processing," which can increase customer revenue by enhancing user experience and can also reduce costs through paperless and virtually error-free electronic transactions that can be completed significantly quicker than paper-based procedures. To date, the Company primarily has delivered biometric and electronic signature solutions to channel partners and end-user customers in the financial services industry.
	The Company's research and development activities have given rise to numerous technologies and products. The Company's core technologies can be referred to as "transaction-enabling" technologies. These technologies include various forms of electronic signatures, such as handwritten biometric, click-to-sign and others, as well signature verification, cryptography and the logging of audit trails to show signers' intent. These technologies can enable secure, legal and regulatory compliant electronic transactions that can enhance customer experience at a fraction of the time and cost required by traditional, paper-based processes. The Company's products include SignatureOne® Ceremony® Server, the iSign® suite of products and services, including iSign® Enterprise and iSign® Console™, Sign-it® and the iSign® toolkits.
	Going Concern
	The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As of September 30, 2013, the Company's accumulated deficit was approximately $ 117,684, and for the nine months ended September 30, 2013, the Company had incurred a net loss of $3,264. The Company also has a working capital deficit at September 30, 2013, of approximately $1,417. The Company has primarily met its working capital needs through the issuance of debt and sale of equity securities. As of September 30, 2013, the Company's cash balance was approximately $287. These factors raise substantial doubt about the Company's ability to continue as a going concern.
	There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Revenue recognition
	For products sold under perpetual license, the Company recognizes revenue upon shipment, provided that persuasive evidence of an arrangement exists, collection is determined to be probable, all non-recurring engineering work necessary to enable the Company's product to function within the customer's application has been completed and the Company's product has been delivered according to specifications. For software sold under a term license, the Company recognizes revenue over the term of the license granted. Revenue from customization of software is recognized when all engineering work necessary to enable the Company's products to function within the customer's application has been completed, and the Company has delivered its product according to specifications.
	Software license agreements may contain multiple elements, including upgrades and enhancements, products deliverable on a when and if available basis and post contract support.
	For arrangements with multiple deliverables the Company allocates consideration at the inception of an arrangement to all of its deliverables based on their relative selling prices. In the absence of the vendor-specific objective evidence or third-party evidence of the selling prices, Management's best estimate of the selling prices is used. For the Company's tangible products containing software and hardware elements that function together and deliver the tangible products' essential functionality is accounted for under the multiple-element arrangements revenue recognition guidance discussed above.
	Maintenance revenue is recorded for post-contract support and upgrades or enhancements, which is paid for in addition to license fees, and is recognized as costs are incurred or over the support period whichever is longer. For undelivered elements where objective and reliable evidence of fair value does not exist, revenue is deferred and subsequently recognized when delivery has occurred and when fair value has been determined.
	Treasury Stock
	Shares of Common Stock returned to, or repurchased by the Company are recorded at cost and are included as a separate component of stockholders' equity. Under the cost method, the gross cost of the shares reacquired is charged to a contra equity account entitled treasury stock. The equity accounts that were credited for the original share issuance (Common Stock, paid-in capital in excess of par, etc.) remain intact. When the treasury shares are reissued, proceeds in excess of cost are credited to a paid-in capital account. Any deficiency is charged to retained earnings (unless paid-in capital from previous treasury share transactions exists, in which case the deficiency is charged to that account, with any excess charged to retained earnings). At September 30, 2013, the total value of treasury stock was $325.
	Accounting Changes and Recent Accounting Pronouncements
	Accounting Standards Issued But Not Yet Adopted
	Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company's financial position, results of operations and cash flows.

Accounts_receivable_and_revenu

Accounts receivable and revenue concentrations	9 Months Ended
	Sep. 30, 2013
Accounts Receivable and revenue concentrations [Abstract]	'
Accounts receivable and revenue concentrations	'
	2. Accounts receivable and revenue concentrations
	The following table summarizes accounts receivable and revenue concentrations:
		Accounts Receivable		Total Revenue		Total Revenue
		As of September 30,		for the three months		for the nine months
				ended September 30,		ended September 30,
		2013	2012	2013	2012	2013	2012
	Customer #1	26%
	Customer #2	47%	37%	31%		18%	10%
	Customer #3		10%
	Customer #4		13%		13%
	Customer #5		22%		29%		10%
	Customer #6						26%
	Customer #7			10%		12%
	Total concentration	73%	82%	41%	42%	30%	46%

Patents

Patents	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Patents	'
	3. Patents
	The Company performs intangible asset impairment analysis at least annually in accordance with the relevant accounting guidance. The Company periodically reassesses the lives of its patents and tests for impairment in order to determine whether the book value of each patent exceeds the fair value of each patent. Fair value is determined by estimating future cash flows from the products that are and will be protected by the patents and taking into account the factors listed in Critical Accounting Policies in the Company's Annual Report on Form 10-K.
	Management completed an analysis of the Company's patents as of December 31, 2012. Based on that analysis, the Company concluded that no impairment of the carrying value of the patents existed. The Company believes that no events or circumstances occurred or changed during the three and nine months ended September 30, 2013, and therefore concluded that no impairment in the carrying values of the patents existed at September 30, 2013.
	Amortization of patent costs was $92 and $275 for the three and nine-month periods ended September 30, 2013 and $90 and $274 for the three and nine-month periods ended September 30, 2012, respectively.
	Intangible Assets
	The following table summarizes intangible assets:
	Amortizable intangible assets:	30-Sep-13		31-Dec-12
		Carrying	Accumulated	Carrying	Accumulative
		Amount	Amortization	Amount	Amortization
	Patents	$	$	$	$
		6,746	-5,366	6,746	-5,091

Shortterm_notes_payable

Short-term notes payable	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Short-term notes payable	'
	4. Short-term notes payable
	The Company borrowed $250 from Phoenix Banner Holding LLC, $250 from Kendu Partners Company and $250 from Michael W. Engmann, each a related party, on August 3, 2013, September 3, 2013, and September 27, 2013, respectively. The aggregate $750 was borrowed in exchange for three unsecured demand notes that bear interest at the rate of 10% per annum. At September 30, 2013 accrued interest associated with the above notes was $6. The Company used the proceeds for working capital and general corporate purposes.
	In April 2013, the Company borrowed $250 in the form of a demand note from Phoenix Banner Holdings LLC, with an interest rate of 10% per annum. The note plus $2 of accrued interest was paid in May 2013.

Derivative_Liability

Derivative Liability	9 Months Ended
	Sep. 30, 2013
Derivative liability [Abstract]	'
Derivative liability	'
	5. Derivative liability
	The Company has determined that certain warrants related to the Company's financings and the embedded conversion feature on the Series A-1 Cumulative Convertible Preferred Stock (the "Series A-1 Preferred Stock") require liability classification because of certain provisions that may result in an adjustment to the number of shares upon settlement and an adjustment to their exercise or conversion. The fair value of the embedded conversion feature for the Series A-1 Preferred Stock at September 30, 2013, and December 31, 2012, was insignificant.
	In December 2010, the Company determined that the embedded conversion feature of its Series B Participating Convertible Preferred Stock (the "Series B Preferred Stock") and Series C Participating Convertible Preferred Stock (the "Series C Preferred Stock") required liability classification due to the impact the anti-dilution provisions could have had on the number of shares issuable upon conversion. In March 2011, the Company amended its Amended and Restated Certificate of Designation for its Series B Preferred Stock and its Certificate of Designation for its Series C Preferred Stock by amending the anti-dilution provisions. Under the amendments, in the event additional stock is issued at a price lower than the conversion price then in effect, the new conversion price of the Series B and/or Series C Preferred Stock cannot be (A) lower than the average closing market price for the Common Stock for the twenty (20) trading days prior to the closing date of a transaction requiring an adjustment in the conversion price or (B) greater than the conversion price then in effect. The amendments were approved by the Company's Board of Directors and the necessary majorities of the Company's Series A-1, Series B and Series C Preferred Stock, and were filed with the Delaware Secretary of State on March 31, 2011. As a result of these amendments, the Series B Preferred Stock and Series C Preferred Stock no longer require liability classification.
	The fair value of the outstanding derivative liabilities at September 30, 2013, and December 31, 2012, was $37 and $128, respectively.
	The Company uses the Black-Scholes pricing model to calculate fair value of its warrant derivative liabilities. Key assumptions used to apply these models are as follows:
		30-Sep-13	31-Dec-12
	Expected term	0.3 to 2.1 years	0.3 to 2.8 years
	Volatility	202.10%	205.30%
	Risk-free interest rate	2.64%	1.78%
	Dividend yield	0%	0%
	Fair value measurements:
	Assets and liabilities measured at fair value as of September 30, 2013 and December 31, 2012, are as follows:
		Value at	Quoted	Significant	Significant
			prices in	other	unobservable
			active	observable	inputs
			markets	inputs
		30-Sep-13	(Level 1)	(Level 2)	(Level 3)
	Derivative liability	$	$	$	$
		37	-	-	37
		31-Dec-12
	Derivative liability	$	$	$	$
		128	-	-	128
	The fair value framework requires a categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets and liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:
	Level 1: Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
	Level 2: Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
	Level 3: Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
	The Company's assets and liabilities measured at fair value, whether recurring or non-recurring, at September 30, 2013, and December 31, 2012, and the fair value calculation input hierarchy level that we have determined applies to each asset and liability category.
	Changes in the fair market value of the Level 3 derivative liability for the nine-month period ended September 30, 2013 are as follows:
		Derivative Liability
	Balance at January 1, 2013	$
		128
	Gain on derivative liability	-91
	Balance at September 30, 2013	$
		37

Net_loss_per_share

Net loss per share	9 Months Ended
	Sep. 30, 2013
Net loss per share [Abstract]	'
Net loss per share	'
	6. Net loss per share
	The Company calculates basic net loss per share, based on the weighted average number of shares outstanding, and when applicable, diluted income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding.
	For the nine-months ended September 30, 2013, 70,017 shares of Common Stock subject to outstanding options, 7,222 shares of Series A-1 Preferred Stock, 249,941 shares of Series B Preferred Stock, 199,801 shares of Series C Preferred Stock, 64,401 shares of Series D-1 Convertible Preferred Stock (the "Series D-1 Preferred Stock") and 90,215 shares of Series D-2 Convertible Preferred Stock (the "Series D-2 Preferred Stock") on an as converted basis and 129,335 shares issuable upon exercise of warrants were excluded from the calculation of dilutive earnings per share as the exercise of such options and warrants would be anti-dilutive.
	For the nine-months ended September 30, 2012, 46,080 shares of Common Stock subject to outstanding options, 6,540 shares of Series A-1 Preferred Stock, 226,434 shares of Series B Preferred Stock and 181,010 shares of Series C Preferred Stock on an as converted basis and 149,831 shares issuable upon exercise of warrants were excluded from the calculation of dilutive earnings per share as the exercise of such options and warrants would be anti-dilutive.
	The following table is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted EPS calculations and sets forth potential shares of common stock that are not included in the diluted net loss per share calculation as the effect is antidilutive:
		Three Months Ended		Nine Months Ended
		September 30,	September 30,	September 30,	September 30,
		2013	2012	2013	2012
	Numerator-basic and diluted net loss	$	$	$	$
		-1,430	-1,172	-4,954	-3,835
	Denominator-basic or diluted weighted average number of common shares outstanding	225,824	224,492	225,810	222,198
	Net loss per share - basic and diluted	$	$	$	$
		-0.01	-0.01	-0.02	-0.02

Equity

Equity	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	7. Equity
	Share-based compensation expense is based on the estimated grant date fair value of the portion of share-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the single option valuation approach. Forfeitures of share-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the nine-months ended September 30, 2013 and 2012, was approximately 9.73% and 9.60%, respectively, based on historical data.
	Valuation and Expense Information:
	The weighted-average fair value of stock-based compensation is based on the single option valuation approach. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized using the accrual method over the vesting period of the options. The fair value calculations are based on the following assumptions:
		Nine-months Ended	Nine-months Ended
		30-Sep-13	30-Sep-12
	Risk free interest rate	0.35% - 4.92%	0.62% - 5.11%
	Expected life (years)	2.82 - 7.00	2.82 - 7.00
	Expected volatility	91.99% - 198.38%	91.99% - 180.36%
	Expected dividends	None	None
	The Company granted 26,554 stock options during the three and nine months ended September 30, 2013. There were no stock options exercised during the three and nine months ended September 30, 2013.
	The Company granted 2,000 stock options during the three and nine months ended September 30, 2012, and 184 stock options were exercised for $12 in cash.
	The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three and nine months ended September 30, 2013 and 2012.
		Three Months Ended September 30,		Nine months Ended September 30,
		2013	2012	2013	2012
	Research and development	$	$	$	$
		36	45	153	166
	Sales and marketing	13	27	55	70
	General and administrative	75	30	320	117
	Director options	7	7	32	23
	Stock-based compensation expense	$	$	$	$
		131	109	560	376
	A summary of option activity under the Company's plans as of September 30, 2013 and 2012 is as follows:
	Options	2013				2012
		Shares	Weighted	Weighted	Aggregate	Shares	Weighted	Weighted	Aggregate
			Average	Average	Intrinsic		Average	Average	Intrinsic
			Exercise	Remaining	Value		Exercise	Remaining	Value
			Price	Contractual			Price	Contractual
				Term				Term
	Outstanding at January 1,	44,529	$0.05		$	51,353	$0.09		$
					-				4,449
	Granted	26,554	$0.04		$	2,000	$0.06		$
					-				120
	Exercised	-	$     -		$	-184	$0.07		$
					-				-2
	Forfeited or expired	-1,066	$0.13		$	-7,089	$0.26		$
					-				-1,830
	Outstanding at September 30	70,017	$0.05	5.24	$	46,080	$0.06	5.38	$
					-				2,237
	Vested and expected to vest at September 30	63,204	$0.05	5.24	$	41,656	$0.06	5.38	$
					-				2,465
	Exercisable at September 30	38,793	$0.05	4.73	$	21,411	$0.07	4.96	$
					-				1,603
	The following tables summarize significant ranges of outstanding and exercisable options as of September 30, 2013:
	Range of Exercise Prices	Options Outstanding			Options Exercisable
		Number	Weighted	Weighted	Number	Weighted
		Outstanding	Average	Average	Outstanding	Average
			Remaining	Exercise		Exercise
			Contractual	Price		Price
			Life (in years)
	$ 0.02 - $ 0.50	70,017	5.24	$0.05	38,793	$0.05
	The following tables summarize the Company's unvested shares as of September 30, 2013:
	Non-vested Shares	Shares	Weighted Average
			Grant-Date
			Fair Value
	Unvested at January 1, 2013	21,210	$0.05
	Granted	26,554	$0.04
	Forfeited	(682)	$0.14
	Vested	(15,858)	$0.06
	Unvested at September 30, 2013	31,224	$0.04
	As of September 30, 2013, there was $ 399 of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of 2.75 years.
	Information with respect to the class of Preferred Stock at September 30, 2013 is as follows:
	Class of	Issue Date	Annual	Annual	Liquidation	Conversion	YTD	Total	Common
Preferred	Dividend		Dividend	Preference	Price	Dividend	Preferred	Shares to be
Stock			Payable, in			Shares in	Shares	issued if
			Cash or In			Kind	Outstanding	Fully
			Kind					Converted
Series A-1	May-08	8%	Quarterly in Arrears	$1.00	$0.14	58	1,011	7,221
Series B	Aug-10	10%	Quarterly in Arrears	$1.50	$0.04	771	10,830	250,115
Series C	December/March 2011	10%	Quarterly in Arrears	$1.50	$0.02	320	4,496	199,822
Series D-1	November 2012/May 2013	10%	Quarterly in Arrears	$1.00	$0.02	95	1,449	64,400
Series D-2	November 2012/May 2013	10%	Quarterly in Arrears	$1.00	$0.05	288	4,511	90,220
Total						1,532
Series A-1 Preferred Stock
In May 2008, the Company issued shares of the Company's Series A Cumulative Convertible Preferred Stock in exchange for certain debt. The Series A Cumulative Convertible Preferred Stock was subsequently exchanged in October 2008 for an equivalent number of shares of Series A-1 Preferred Stock. The shares of Series A-1 Preferred Stock are convertible any time and are subordinate to the Series B, Series C and Series D Preferred Stock.
Series B Preferred Stock
In August 2010, the Company completed the conversion of all of its outstanding indebtedness and issued shares of Series B Preferred Stock in accordance with an executed Exchange Agreement entered into with Phoenix Venture Fund LLC and certain other holders of the Company's indebtedness (the "Recapitalization"). The Company sold additional shares of Series B Preferred Stock for cash (the "Series B Financing") in addition to the conversion of its outstanding debt. The proceeds were used for working capital and general corporate purposes, in each case in the ordinary course of business, and to pay fees and expenses associated with the Recapitalization and Series B Financing. The shares of Series B Preferred Stock are convertible at any time and are subordinate to the Series C and Series D Preferred Stock.
Series C Preferred Stock
In December 2010, the Company completed the sale of shares of Series C Preferred Stock through a Securities Purchase Agreement with Phoenix Venture Fund LLC and certain other investors. The proceeds were used for working capital and general corporate purposes, in each case in the ordinary course of business, and to pay fees and expenses associated with the sale of the Series C Preferred Stock. The shares of Series C Preferred Stock are convertible into Common Stock at any time and are subordinate to the Series D Preferred Stock.
In March 2011, the Company issued shares of its Series C Preferred Stock and warrants to purchase shares of Common Stock to its President as part of a professional services agreement. In addition the Company sold additional shares of Series C Preferred Stock for cash.
In January 2012, the Company received 6,500 shares of Common Stock from Phoenix Venture Fund LLC ("Phoenix") in settlement of a 16b claim brought by a Company stockholder against Phoenix, certain affiliates and the Company, as a nominal defendant. The Common Stock was valued at $325. In settlement of an indemnification claim brought by Phoenix in March 2012, resulting from the settlement of the 16b claim in January 2012, the Company issued to Phoenix 278 shares of Series C Preferred Stock valued at $417. The Company booked a $418 accretion amount for the beneficial conversion feature on the 278 shares of Series C Preferred Stock.
Series D Preferred Stock
In November 2012, stockholders approved an increase in the Company's authorized capital and the issuance of Series D-1 and Series D-2 Preferred Stock.
In May 2013, the Company completed a private placement of 230 units of Series D Preferred Stock consisting of one (1) share of Series D-1 Preferred Stock and four (4) shares of Series D-2 Preferred Stock. The Series D-1 Preferred Stock can convert to Common Stock at a price of $0.0225 per share, and the Series D-2 Preferred Stock can convert to Common Stock at a price of $0.05 per share. The private placement provided $1,150 in proceeds to the Company. The proceeds were used for general working capital purposes and to repay a bridge loan that was secured in April 2013 from Phoenix Banner Holdings LLC in the amount of $250 plus $2 in accrued interest.
In November 2012, the Company converted approximately $3,099 of short-term debt and accrued interest into shares of Series D Preferred Stock net of offering costs of $190. The Company sold, for cash in a private placement, 1,082 of additional shares of Series D-2 Preferred Stock at a purchase price of $1.00 per share and received $967 net of offering costs of $115. The material terms of the Series D-1 and Series D-2 Preferred Stock, other than the initial conversion price, are essentially the same. The shares of Series D Preferred Stock are convertible at any time and rank senior to the Company's outstanding shares of Series A-1, Series B and Series C Preferred Stock, and of Common Stock with respect to dividend rights and liquidation preferences.
Preferred Stock Voting and Other Rights
Generally, the Company's Preferred Stock votes together on an as converted basis with the holders of Common Stock. In addition, the Company's Preferred Stock enjoys certain protective provisions, a liquidation preference and anti-dilution protection that are similar to one another.
Warrants
Series C Preferred Stock Warrants
Each investor who purchased shares of Series C Preferred Stock in the financing transactions which closed on December 31, 2010 and March 31, 2011 received a warrant to purchase a number of shares of Common Stock equal to the aggregate number of shares of Series C Preferred Stock purchased by the investor divided by 0.0225. Each warrant issued in connection with the Series C Financing has an exercise price of $0.0225 per share and is exercisable in whole or in part, including by means of cashless exercise, for a period of three years from the date of issuance. In February and March 2012, an aggregate of 35,162 warrants were exercised, 28,678 warrants were exercised by holders of the Series C Preferred Stock warrants and 6,484 warrants were exercised by the holders of the warrants other than the Series C Preferred Stock warrants. Of the Series C Preferred Stock warrants exercised, 6,222 were exercised for cash for which the Company received $213 and 22,456 were exercised on a cashless basis. The Company issued 23,928 shares of Common Stock related to these exercises. If the remaining outstanding Series C Warrants are exercised in their entirety, the Company would issue 107,623 shares of Common Stock.
Other Warrants
In January 2013, 1,300 warrants were exercised for $29 in cash. In February and March 2012, 6,484 warrants were exercised by the holders of the warrants other than the Series C Preferred Stock warrants described above. At September 30, 2013, 21,712 shares of Common Stock were reserved for issuance upon exercise of other outstanding warrants, in addition to the 107,623 shares of Common Stock issuable upon exercise of the Series C Warrants described above.
A summary of the warrant activity is as follows:
	30-Sep-13		31-Dec-12
	Warrants	Weighted	Warrants	Weighted
		Average		Average
		Exercise Price		Exercise Price
Outstanding at beginning of period	151,722	$0.03	182,644	$0.03
Issued	-	-	8,643	$0.05
Exercised	(1,300)	$0.02	(35,162)	$0.03
Expired	(21,087)	$0.04	(4,403)	-
Outstanding at end of period	129,335	$0.03	151,722	$0.03
Exercisable at end of period	129,335	$0.03	151,722	$0.03
A summary of the status of the warrants outstanding and exercisable as of September 30, 2013, is as follows:
Number of Warrants	Weighted Average	Weighted Average
	Remaining Life	Exercise Price per
		share
120,692	0.44	$0.02
8,643	1.86	$0.05
129,335	0.53	$0.03

Nature_of_business_basis_of_pr1

Nature of business, basis of presentation and summary of significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2013
Summary of Significant Accounting Policies	'
Basis of presentation	'
	The accompanying unaudited condensed consolidated financial statements of Communication Intelligence Corporation and its subsidiary (the "Company" or "CIC") have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year.
Revenue Recognition, Software	'
	For products sold under perpetual license, the Company recognizes revenue upon shipment, provided that persuasive evidence of an arrangement exists, collection is determined to be probable, all non-recurring engineering work necessary to enable the Company's product to function within the customer's application has been completed and the Company's product has been delivered according to specifications. For software sold under a term license, the Company recognizes revenue over the term of the license granted. Revenue from customization of software is recognized when all engineering work necessary to enable the Company's products to function within the customer's application has been completed, and the Company has delivered its product according to specifications.
Revenue Recognition, Multiple-deliverable Arrangements	'
	Software license agreements may contain multiple elements, including upgrades and enhancements, products deliverable on a when and if available basis and post contract support.
	For arrangements with multiple deliverables the Company allocates consideration at the inception of an arrangement to all of its deliverables based on their relative selling prices. In the absence of the vendor-specific objective evidence or third-party evidence of the selling prices, Management's best estimate of the selling prices is used. For the Company's tangible products containing software and hardware elements that function together and deliver the tangible products' essential functionality is accounted for under the multiple-element arrangements revenue recognition guidance discussed above.
	Maintenance revenue is recorded for post-contract support and upgrades or enhancements, which is paid for in addition to license fees, and is recognized as costs are incurred or over the support period whichever is longer. For undelivered elements where objective and reliable evidence of fair value does not exist, revenue is deferred and subsequently recognized when delivery has occurred and when fair value has been determined.
Treasury stock	'
	Shares of Common Stock returned to, or repurchased by the Company are recorded at cost and are included as a separate component of stockholders' equity. Under the cost method, the gross cost of the shares reacquired is charged to a contra equity account entitled treasury stock. The equity accounts that were credited for the original share issuance (Common Stock, paid-in capital in excess of par, etc.) remain intact. When the treasury shares are reissued, proceeds in excess of cost are credited to a paid-in capital account. Any deficiency is charged to retained earnings (unless paid-in capital from previous treasury share transactions exists, in which case the deficiency is charged to that account, with any excess charged to retained earnings).
Patents Impairment	'
	The Company performs intangible asset impairment analysis at least annually in accordance with the relevant accounting guidance. The Company periodically reassesses the lives of its patents and tests for impairment in order to determine whether the book value of each patent exceeds the fair value of each patent. Fair value is determined by estimating future cash flows from the products that are and will be protected by the patents and taking into account the factors listed in Critical Accounting Policies in the Company's Annual Report on Form 10-K.
Derivatives policy	'
	The Company has determined that certain warrants related to the Company's financings and the embedded conversion feature on the Series A-1 Cumulative Convertible Preferred Stock (the "Series A-1 Preferred Stock") require liability classification because of certain provisions that may result in an adjustment to the number of shares upon settlement and an adjustment to their exercise or conversion. The fair value of the embedded conversion feature for the Series A-1 Preferred Stock at September 30, 2013, and December 31, 2012, was insignificant.
Fair value measurement	'
	The fair value framework requires a categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets and liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:
	Level 1: Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
	Level 2: Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
	Level 3: Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
Net loss per share	'
	The Company calculates basic net loss per share, based on the weighted average number of shares outstanding, and when applicable, diluted income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding.
Share-Based Compensation, valuation	'
	Share-based compensation expense is based on the estimated grant date fair value of the portion of share-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the single option valuation approach. Forfeitures of share-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	The weighted-average fair value of stock-based compensation is based on the single option valuation approach. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized using the accrual method over the vesting period of the options.

Accounts_receivable_and_revenu1

Accounts receivable and revenue concentrations (Tables)	9 Months Ended
	Sep. 30, 2013
Accounts Receivable and revenue concentrations [Abstract]	'
Summary of accounts receivable and revenue concentrations	'
		Accounts Receivable		Total Revenue		Total Revenue
		As of September 30,		for the three months		for the nine months
				ended September 30,		ended September 30,
		2013	2012	2013	2012	2013	2012
	Customer #1	26%
	Customer #2	47%	37%	31%		18%	10%
	Customer #3		10%
	Customer #4		13%		13%
	Customer #5		22%		29%		10%
	Customer #6						26%
	Customer #7			10%		12%
	Total concentration	73%	82%	41%	42%	30%	46%

Patents_Tables

Patents (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Summary of Intangible Assets	'
	Amortizable intangible assets:	30-Sep-13		31-Dec-12
		Carrying	Accumulated	Carrying	Accumulative
		Amount	Amortization	Amount	Amortization
	Patents	$	$	$	$
		6,746	-5,366	6,746	-5,091

Derivative_Liability_Tables

Derivative Liability (Tables)	9 Months Ended
	Sep. 30, 2013
Derivative liability [Abstract]	'
Key assumptions used to calculate fair value of warrant derivative liabilities	'
		30-Sep-13	31-Dec-12
	Expected term	0.3 to 2.1 years	0.3 to 2.8 years
	Volatility	202.10%	205.30%
	Risk-free interest rate	2.64%	1.78%
	Dividend yield	0%	0%
Liabilities measured at fair value	'
		Value at	Quoted	Significant	Significant
			prices in	other	unobservable
			active	observable	inputs
			markets	inputs
		30-Sep-13	(Level 1)	(Level 2)	(Level 3)
	Derivative liability	$	$	$	$
		37	-	-	37
		31-Dec-12
	Derivative liability	$	$	$	$
		128	-	-	128
Changes in the market value of the Level 3 derivative liability	'
		Derivative Liability
	Balance at January 1, 2013	$
		128
	Gain on derivative liability	-91
	Balance at September 30, 2013	$
		37

Net_loss_per_share_Tables

Net loss per share (Tables)	9 Months Ended
	Sep. 30, 2013
Net loss per share [Abstract]	'
Reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted EPS calculations	'
		Three Months Ended		Nine Months Ended
		September 30,	September 30,	September 30,	September 30,
		2013	2012	2013	2012
	Numerator-basic and diluted net loss	$	$	$	$
		-1,430	-1,172	-4,954	-3,835
	Denominator-basic or diluted weighted average number of common shares outstanding	225,824	224,492	225,810	222,198
	Net loss per share - basic and diluted	$	$	$	$
		-0.01	-0.01	-0.02	-0.02

Equity_Tables

Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity [Abstract]	'
Key assumptions for fair value calculation, stock options	'
		Nine-months Ended	Nine-months Ended
		30-Sep-13	30-Sep-12
	Risk free interest rate	0.35% - 4.92%	0.62% - 5.11%
	Expected life (years)	2.82 - 7.00	2.82 - 7.00
	Expected volatility	91.99% - 198.38%	91.99% - 180.36%
	Expected dividends	None	None
Allocation of stock-based compensation expense related to stock option grants	'
		Three Months Ended September 30,		Nine months Ended September 30,
		2013	2012	2013	2012
	Research and development	$	$	$	$
		36	45	153	166
	Sales and marketing	13	27	55	70
	General and administrative	75	30	320	117
	Director options	7	7	32	23
	Stock-based compensation expense	$	$	$	$
		131	109	560	376
Summary of option activity	'
	Options	2013				2012
		Shares	Weighted	Weighted	Aggregate	Shares	Weighted	Weighted	Aggregate
			Average	Average	Intrinsic		Average	Average	Intrinsic
			Exercise	Remaining	Value		Exercise	Remaining	Value
			Price	Contractual			Price	Contractual
				Term				Term
	Outstanding at January 1,	44,529	$0.05		$	51,353	$0.09		$
					-				4,449
	Granted	26,554	$0.04		$	2,000	$0.06		$
					-				120
	Exercised	-	$     -		$	-184	$0.07		$
					-				-2
	Forfeited or expired	-1,066	$0.13		$	-7,089	$0.26		$
					-				-1,830
	Outstanding at September 30	70,017	$0.05	5.24	$	46,080	$0.06	5.38	$
					-				2,237
	Vested and expected to vest at September 30	63,204	$0.05	5.24	$	41,656	$0.06	5.38	$
					-				2,465
	Exercisable at September 30	38,793	$0.05	4.73	$	21,411	$0.07	4.96	$
					-				1,603
Summary of the significant ranges of outstanding and exercisable options	'
	Range of Exercise Prices	Options Outstanding			Options Exercisable
		Number	Weighted	Weighted	Number	Weighted
		Outstanding	Average	Average	Outstanding	Average
			Remaining	Exercise		Exercise
			Contractual	Price		Price
			Life (in years)
	$ 0.02 - $ 0.50	70,017	5.24	$0.05	38,793	$0.05
Summary of the status of the Company's non-vested shares	'
	Non-vested Shares	Shares	Weighted Average
			Grant-Date
			Fair Value
	Unvested at January 1, 2013	21,210	$0.05
	Granted	26,554	$0.04
	Forfeited	(682)	$0.14
	Vested	(15,858)	$0.06
	Unvested at September 30, 2013	31,224	$0.04
Information with respect to the class of preferred stock	'
	Class of	Issue Date	Annual	Annual	Liquidation	Conversion	YTD	Total	Common
	Preferred		Dividend	Dividend	Preference	Price	Dividend	Preferred	Shares to be
	Stock			Payable, in			Shares in	Shares	issued if
				Cash or In			Kind	Outstanding	Fully
				Kind					Converted
	Series A-1	May-08	8%	Quarterly in Arrears	$1.00	$0.14	58	1,011	7,221
	Series B	Aug-10	10%	Quarterly in Arrears	$1.50	$0.04	771	10,830	250,115
	Series C	December/March 2011	10%	Quarterly in Arrears	$1.50	$0.02	320	4,496	199,822
	Series D-1	November 2012/May 2013	10%	Quarterly in Arrears	$1.00	$0.02	95	1,449	64,400
	Series D-2	November 2012/May 2013	10%	Quarterly in Arrears	$1.00	$0.05	288	4,511	90,220
	Total						1,532
Summary of the warrants issued	'
		30-Sep-13		31-Dec-12
		Warrants	Weighted	Warrants	Weighted
			Average		Average
			Exercise Price		Exercise Price
	Outstanding at beginning of period	151,722	$0.03	182,644	$0.03
	Issued	-	-	8,643	$0.05
	Exercised	(1,300)	$0.02	(35,162)	$0.03
	Expired	(21,087)	$0.04	(4,403)	-
	Outstanding at end of period	129,335	$0.03	151,722	$0.03
	Exercisable at end of period	129,335	$0.03	151,722	$0.03
Status of the warrants outstanding	'
	Number of Warrants	Weighted Average	Weighted Average
		Remaining Life	Exercise Price per
			share
	120,692	0.44	$0.02
	8,643	1.86	$0.05
	129,335	0.53	$0.03

Nature_of_business_basis_of_pr2

Nature of business, basis of presentation and summary of significant accounting policies (Details Textual) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Nature Of Business Basis Of Presentation And Summary Of Significant Accounting Policies Textual [Abstract]	'	'	'	'	'	'
Accumulated deficit	($117,684)	'	($117,684)	'	($114,420)	'
Net loss	-887	-812	-3,264	-2,376	'	'
Working capital deficit	1,417	'	1,417	'	'	'
Cash and Cash Equivalents, at Carrying Value	287	501	287	501	486	307
Treasury Stock, Value	$325	'	$325	'	$325	'

Accounts_receivable_and_revenu2

Accounts receivable and revenue concentrations (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Concentration Risk [Line Items]	'	'	'	'
Concentration risk percentage of gross receivables	73.00%	82.00%	73.00%	82.00%
Concentration risk, percentage of total revenue	41.00%	42.00%	30.00%	46.00%
Accounts Receivable [Member] | Customer 1	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk percentage of gross receivables	26.00%	'	26.00%	'
Accounts Receivable [Member] | Customer 2	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk percentage of gross receivables	47.00%	37.00%	47.00%	37.00%
Accounts Receivable [Member] | Customer 3	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk percentage of gross receivables	'	10.00%	'	10.00%
Accounts Receivable [Member] | Customer 4	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk percentage of gross receivables	'	13.00%	'	13.00%
Accounts Receivable [Member] | Customer 5	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk percentage of gross receivables	'	22.00%	'	22.00%
Sales Revenue, Services, Net [Member] | Customer 2	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage of total revenue	31.00%	'	18.00%	10.00%
Sales Revenue, Services, Net [Member] | Customer 4	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage of total revenue	'	13.00%	'	'
Sales Revenue, Services, Net [Member] | Customer 5	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage of total revenue	'	29.00%	'	10.00%
Sales Revenue, Services, Net [Member] | Customer 6	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage of total revenue	'	'	'	26.00%
Sales Revenue, Services, Net [Member] | Customer 7	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage of total revenue	10.00%	'	12.00%	'

Patents_Details

Patents (Details) (Patents [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Patents [Member]	'	'
Amortizable intangible assets	'	'
Finite-lived intangible assets, gross	$6,746	$6,746
Finite-Lived intangible assets, accumulated amortization	($5,366)	($5,091)

Patents_Details_Textual

Patents (Details Textual) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Amortization of patent costs	$92	$90	$275	$274
Patents impairment	$0	$0	$0	$0

Shortterm_notes_payable_Detail

Short-term notes payable (Details Textual) (USD $)	9 Months Ended			1 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	31-May-13	Aug. 03, 2013	Apr. 23, 2013	Sep. 03, 2013	Sep. 30, 2013
			Unsecured demand notes [Member]	Unsecured demand notes [Member]	Unsecured demand notes [Member]	Unsecured demand notes [Member]	Unsecured demand notes [Member]	Unsecured demand notes [Member]
			Note	Phoenix Banner Holding LLC [Member]	Phoenix Banner Holding LLC [Member]	Phoenix Banner Holding LLC [Member]	Kendu Partners Company [Member]	Michael W. Engmann [Member]
Short-term Debt [Line Items]	'	'	'	'	'	'	'	'
Short-term notes payable	$750	'	'	'	$250	$250	$250	$250
Interest rate percentage, per annum	'	'	'	'	10.00%	10.00%	10.00%	10.00%
Number of unsecured demand notes	'	'	3	'	'	'	'	'
Payment on short term debt	250	225	'	250	'	'	'	'
Accrued interest associated with notes payable	'	'	$6	$2	'	'	'	'

Derivative_liability_Details

Derivative liability (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Volatility	202.10%	205.30%
Risk-free interest rate	2.64%	1.78%
Dividend yield	$0	$0
Minimum [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Expected term	'3 months 18 days	'3 months 18 days
Maximum [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Expected term	'2 years 1 month 6 days	'2 years 9 months 18 days

Derivative_Liability_Details1

Derivative Liability (Details1) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Liabilities measured at fair value	'	'
Derivative liability	$37	$128
Fair Value, Inputs, Level 1 [Member]	'	'
Liabilities measured at fair value	'	'
Derivative liability	'	'
Fair Value, Inputs, Level 2 [Member]	'	'
Liabilities measured at fair value	'	'
Derivative liability	'	'
Fair Value, Inputs, Level 3 [Member]	'	'
Liabilities measured at fair value	'	'
Derivative liability	$37	$128

Derivative_liability_Details_2

Derivative liability (Details 2) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'
Balance at beginning of period	$128
Gain on derivative liability	-91
Balance at end of period	$37

Derivative_Liability_Details_T

Derivative Liability (Details Textual) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Derivative Liability, Fair Value, Net [Abstract]	'	'
Fair value of the derivative liability	$37	$128

Net_loss_per_share_Details

Net loss per share (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share Reconciliation [Abstract]	'	'	'	'
Net Income (Loss) Attributable to Parent	($1,430)	($1,172)	($4,954)	($3,835)
Denominator-basic or diluted weighted average number of common shares outstanding	225,824	224,492	225,810	222,198
Net loss per share - basic and diluted	($0.01)	($0.01)	($0.02)	($0.02)

Net_loss_per_share_Details_Tex

Net loss per share (Details Textual)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Series A-1 Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	7,222	6,540
Series B Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	249,941	226,434
Series C Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	199,801	181,010
Series D-1 Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	64,401	'
Series D-2 Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	90,215	'
Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	70,017	46,080
Warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, shares	129,335	149,831

Equity_Details

Equity (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]	'	'
Risk-free interest rate, minimum	0.35%	0.62%
Risk-free interest rate, maximum	4.92%	5.11%
Expected volatility, minimum	91.99%	91.99%
Expected volatility, maximum	198.38%	180.36%
Expected dividends	$0	$0
Minimum [Member]	'	'
Fair value assumptions, stock options	'	'
Expected life (years)	'2 years 9 months 18 days	'2 years 9 months 18 days
Maximum [Member]	'	'
Fair value assumptions, stock options	'	'
Expected life (years)	'7 years	'7 years

Equity_Details_1

Equity (Details 1) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$131	$109	$560	$376
Research and Development Expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	36	45	153	166
Selling and Marketing Expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	13	27	55	70
General and Administrative Expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	75	30	320	117
Director Options [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$7	$7	$32	$23

Equity_Details_2

Equity (Details 2) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Summary of stock options outstanding	'	'	'
Stock Options Outstanding, Beginning Balance	44,529	51,353	'
Stock Options, granted	26,554	2,000	'
Stock Options, exercised	'	-184	'
Stock Options, forfeited, or expired	-1,066	-7,089	'
Stock Options Outstanding, Ending Balance	70,017	46,080	'
Stock Options, Vested and expected to vest at ending balance	63,204	41,656	'
Stock Options Exercisable at ending balance	38,793	21,411	'
Weighted Average Exercise Price, Beginning Period	$0.05	$0.09	'
Weighted Average Exercise Price, Granted	$0.04	$0.06	'
Weighted Average Exercise Price, Exercised	'	$0.07	'
Weighted Average Exercise Price, Forfeited, or expired	$0.13	$0.26	'
Weighted Average Exercise Price, Ending Period	$0.05	$0.06	'
Weighted Average Exercise Price, Vested and expected to vest at ending balance	$0.05	$0.06	'
Weighted Average Exercise Price, Exercisable at ending balance	$0.05	$0.07	$0.05
Weighted Average Remaining Contractual Term, ending balance	'5 years 2 months 12 days	'5 years 3 months 18 days	'
Weighted Average Remaining Contractual Term, vested and expected to vest at ending balance	'5 years 2 months 12 days	'5 years 3 months 18 days	'
Weighted Average Remaining Contractual Term, excercisable at ending balance	'4 years 8 months 12 days	'4 years 10 months 24 days	'
Aggregate Intrinsic Value, Beginning Balance	'	$4,449	'
Aggregate Intrinsic Value, Granted	'	120	'
Aggregate Intrinsic Value, Exercised	'	-2	'
Aggregate Intrinsic Value, Forfeited or expired	'	-1,830	'
Aggregate Intrinsic Value, Ending Balance	'	2,237	'
Aggregate Intrinsic Value, Vested and expected to vest at ending balance	'	2,465	'
Aggregate Intrinsic Value, Exercisable at ending balance	'	$1,603	'

Equity_Details_3

Equity (Details 3) (Range One [Member], USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013
Range One [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price Range, Lower Range Limit	$0.02
Exercise Price Range, Upper Range Limit	$0.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]	'
Number of Outstanding Options	70,017
Outstanding Options, Weighted Average Remaining Contractual Term (in years)	'5 years 2 months 12 days
Outstanding Options, Weighted Average Exercise Price	$0.05
Exercisable Options, Number Outstanding	38,793
Exercisable Options, Weighted Average Exercise Price	$0.05

Equity_Details_4

Equity (Details 4) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013
Equity Instruments, Options, Nonvested Shares Roll-Forward	'
Non-vested shares, Beginning Balance	21,210
Non-vested shares, granted	26,554
Non-vested shares, forfeited, or expired	-682
Non-vested shares, vested	-15,858
Stock Options Outstanding, Ending Balance	31,224
Weighted Average Grant Date Fair Value, Options Nonvested at beginning of period	$0.05
Weighted Average Grant Date Fair Value, Options nonvested, grants in period	$0.04
Weighted Average Grant Date Fair Value, Options nonvested, forfeited in period	$0.14
Weighted Average Grant Date Fair Value, Options nonvested, vested in period	$0.06
Weighted Average Grant Date Fair Value, Options nonvested at end of period	$0.04

Equity_Details_5

Equity (Details 5) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
YTD Dividend Shares in Kind	$1,532,000	'
Series A-1 Preferred Stock [Member]	'	'
Issue Date	'May 2008	'
Annual Dividend	8.00%	'
Annual Dividend Payable, in Cash or In Kind	'Quarterly in Arrears	'
Liquidation Preference	1	'
Conversion Price	$0.14	'
YTD Dividend Shares in Kind	58,000	'
Total Preferred Shares Outstanding	1,011,000	953,000
Common Shares to be Issued if Fully Converted	7,221,000	'
Series B Preferred Stock [Member]	'	'
Issue Date	'August 2010	'
Annual Dividend	10.00%	'
Annual Dividend Payable, in Cash or In Kind	'Quarterly in Arrears	'
Liquidation Preference	1.5	'
Conversion Price	$0.04	'
YTD Dividend Shares in Kind	771,000	'
Total Preferred Shares Outstanding	10,830,000	10,058,000
Common Shares to be Issued if Fully Converted	250,115,000	'
Series C Preferred Stock [Member]	'	'
Issue Date	'December/March 2011	'
Annual Dividend	10.00%	'
Annual Dividend Payable, in Cash or In Kind	'Quarterly in Arrears	'
Liquidation Preference	1.5	'
Conversion Price	$0.02	'
YTD Dividend Shares in Kind	320,000	'
Total Preferred Shares Outstanding	4,496,000	4,175,000
Common Shares to be Issued if Fully Converted	199,822,000	'
Series D-1 Preferred Stock [Member]	'	'
Issue Date	'November 2012/May 2013	'
Annual Dividend	10.00%	'
Annual Dividend Payable, in Cash or In Kind	'Quarterly in Arrears	'
Liquidation Preference	1	'
Conversion Price	$0.02	'
YTD Dividend Shares in Kind	95,000	'
Total Preferred Shares Outstanding	1,449,000	1,124,000
Common Shares to be Issued if Fully Converted	64,400,000	'
Series D-2 Preferred Stock [Member]	'	'
Issue Date	'November 2012/May 2013	'
Annual Dividend	10.00%	'
Annual Dividend Payable, in Cash or In Kind	'Quarterly in Arrears	'
Liquidation Preference	1	'
Conversion Price	$0.05	'
YTD Dividend Shares in Kind	$288,000	'
Total Preferred Shares Outstanding	4,511,000	3,302,000
Common Shares to be Issued if Fully Converted	90,220,000	'

Equity_Details_6

Equity (Details 6) (USD $)	9 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Class Of Warrant Or Right Number Of Warrants Or Rights Roll Forward	'	'
Number of Warrants Outstanding at beginning of period	151,722	182,644
Number Of Warrants Or Rights Issued	'	8,643
Number Of Warrants Or Rights Exercised	-1,300	-35,162
Number Of Warrants Or Rights Expired	-21,087	-4,403
Number of Warrants Outstanding at end of period	129,335	151,722
Number of Warrants Or Rights Exercisable at end of period	129,335	151,722
Excercise Price of Warrants Outstanding at beginning of period	$0.03	$0.03
Exercise Price Of Warrants Issued	'	$0.05
Exercise Price Of Warrants Exercised	$0.02	$0.03
Exercise Price Of Warrants Expired	$0.04	'
Excercise Price of Warrants Outstanding at end of period	$0.03	$0.03
Exercise Price Of WarrantsExercisable at end of period	$0.03	$0.03

Equity_Details_7

Equity (Details 7) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Class of Warrant or Right [Line Items]	'	'	'
Number of Warrants Outstanding and Excercisable	129,335	151,722	182,644
Weighted Average Remaining Life Of Warrants Or Rights	'0 years 8 months 16 days	'	'
Warrants Weighted Average Exercise Price	$0.03	$0.03	$0.03
Warrants Group Two [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Number of Warrants Outstanding and Excercisable	120,692	'	'
Weighted Average Remaining Life Of Warrants Or Rights	'0 years 5 months 9 days	'	'
Warrants Weighted Average Exercise Price	$0.02	'	'
Warrants Group Three [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Number of Warrants Outstanding and Excercisable	8,643	'	'
Weighted Average Remaining Life Of Warrants Or Rights	'1 year 9 months 18 days	'	'
Warrants Weighted Average Exercise Price	$0.05	'	'

Equity_Details_Textual

Equity (Details Textual) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Share-based Arrangements with Employees and Nonemployees [Abstract]	'	'
Option grants estimated average forfeiture rate	9.73%	9.60%
Stock Options, granted	26,554	2,000
Stock Options, exercised	'	184
Proceeds from exercise of stock options, in cash	'	$12
Total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans	$399	'
Unrecognized compensation expense amortization period	'2 years 8 months 12 days	'

Equity_Details_Textual_1

Equity (Details Textual 1) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

In Thousands, except Share data, unless otherwise specified

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

31-May-13

Sep. 30, 2013

31-May-13

Sep. 30, 2013

31-May-13

Nov. 30, 2012

Mar. 31, 2012

Jan. 31, 2012

Nov. 30, 2012

Series D Preferred Stock [Member]

Series D One Preferred Stock [Member]

Series D One Preferred Stock [Member]

Series D Two Preferred Stock [Member]

Series D Two Preferred Stock [Member]

Series D Two Preferred Stock For Cash [Member]

Settlement Of Indemnification Claim [Member]

Settlement Of Indemnification Claim [Member]

Series D Financing [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of aquired treasury shares

'

'

'

'

'

'

'

'

'

'

'

6,500,000

'

Value of aquired treasury shares

'

'

'

$325

'

'

'

'

'

'

'

$325

'

Number of shares issued in private placement

'

'

'

'

'

'

'

'

'

'

278,000

'

'

Stock issued in a private placement, value

'

'

'

'

'

'

'

'

'

1,082

417

'

'

Accretion of Beneficial Conversion Feature on Series C Preferred Shares issued in settlement of the indemnification claim

'

'

'

'

'

'

'

'

'

'

418

'

'

Preferred units, issued in a private placement

'

'

'

'

230,000

'

'

'

'

'

'

'

'

Excercise price of preferred shares (preferred units componenets)

'

'

'

'

'

'

$0.00

'

$0.05

'

'

'

'

Preferred Units, Components

'

'

'

'

'

'

1

'

4

'

'

'

'

Preferred Units, Description

'

'

'

'

'Units of Series D Preferred Shares consisting of one (1) share of Series D-1 Preferred Stock with an exercise price of $0.0025 per share and four (4) shares of Series D-2 Preferred Stock at an exercise price of $0.05 per share.

'

'

'

'

'

'

'

'

Proceeds from issuance of Preferred shares

'

'

'

'

1,150

230

'

920

'

'

'

'

'

Repayment of a bridge loan with Phoenix Banner LLC

'

'

250

225

250

'

'

'

'

'

'

'

'

Accrued interest paid out along with loan repayment

'

'

2

'

2

'

'

'

'

'

'

'

'

Conversion of short-term debt and accrued interest, net of offering costs

'

'

'

'

'

'

'

'

'

'

'

'

3,099

Proceeds from sale of stock, net

'

'

'

'

'

'

'

'

'

967

'

'

'

Purchase price per share for the shares sold in private placement

'

'

'

'

'

'

'

'

'

$1

'

'

'

Offering expenses

'

'

'

'

'

'

'

'

'

$115

'

'

$190

Equity_Details_Textual_2

Equity (Details Textual 2) (USD $)	9 Months Ended		12 Months Ended		2 Months Ended		1 Months Ended	2 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Mar. 31, 2012	Sep. 30, 2013	Jan. 31, 2013	Mar. 31, 2012	Sep. 30, 2013
					Series C Preferred Stock [Member]	Series C Preferred Stock [Member]	Other Holders [Member]	Other Holders [Member]	Other Holders [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Warrants exercise price	$0.03	'	$0.03	$0.03	'	$0.02	'	'	'
Exercise period of warrants	'	'	'	'	'3 years	'	'	'	'
Number of warrants exercised	1,300	'	35,162	'	28,678	'	'	6,484	'
Number of warrants exercised for cash	'	'	'	'	6,222	'	1,300	'	'
Proceeds from exercise of warrants for cash	$29	$213	'	'	'	'	$29	'	'
Proceeds from issuance of common stock, related to warrants exercise	'	'	'	'	$213	'	'	'	'
Number of warrants exercised on cashless basis	'	'	'	'	22,456	'	'	'	'
Number of common shares called by warrants excercise	'	'	'	'	'	23,928	'	'	'
Projected number of common shares, subject to issuance if the remaining warrants are excercised	'	'	'	'	'	107,623	'	'	21,712